Compare AbbVie Inc (ABBV) vs Tesla, Inc. (TSLA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Tesla, Inc. — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while Tesla, Inc. trades at $392.95 (market cap $1.51T). The key difference: Tesla, Inc. is far larger — about 3.4× AbbVie Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Tesla, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | TSLA | |
|---|---|---|
Market Cap | $449.91B | $1.51T |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $489.88 |
52-Week Low | $184.85 | $295.88 |
Enterprise Value | $513.38B | $1.48T |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Tesla (TSLA) trades at $395.04, down 5.89% over the past 24 hours, with a neutral technical signal and mixed earnings history. The stock shows elevated valuation ratios (P/E 369.63, P/S 14.54) against declining profitability margins (net income margin 3.95% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV model, while Q1 2026 deliveries missed estimates amid competitive pressures.
Outlook remains bifurcated: long-term growth depends on AI and autonomy execution, but near-term risks include softening auto demand and high valuation. Analyst consensus price target is $429.91, implying upside, yet sentiment is cautious with 39.51% buy ratings. Investors face volatility from execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
